Search results
The Ova1Plus report calculates a personalized risk score by combining biomarker measurements (including CA-125), menopausal status, and ultrasound results. Ova1Plus equips healthcare providers with the comprehensive ovarian cancer risk intelligence needed to optimize surgical management plans.
The OVA1 algorithm combines the results of these levels with information on the menopause status of the patient to classify the patient into a low- or high-risk group. The results of the OVA1 test can help determine patients needing referral to a gynecologic oncologist for their surgery.
Doctors who use the OVA1 blood test in combination with the CA125 blood test are able to find an average of 96% of all ovarian cancers. Low test results are also able to predict the lack of a malignancy in 98% of studied cases.
13 paź 2009 · OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiologic test results fail to indicate malignancy.
15 wrz 2009 · Amerykański Urząd ds. Żywności i Leków (FDA) wydał zezwolenie na rynkowy debiut OVA1 - nowej generacji testów biochemicznych dedykowanych dla kobiet cierpiących na raka jajnika. Zestaw ten ułatwia lekarzowi ustalenie, czy masa nowotworowa widoczna w badaniu obrazowym ma charakter łagodny, czy też złośliwy.
Ova1 ® is a qualitative serum test that combines the results of five immunoassays into a single numerical result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist.
16 paź 2013 · OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical result. The tests include: CA125 (increased in ovarian tumors) Apolipoprotein A1 (decreased in ovarian tumors) Beta-2 microglobulin (increased in ovarian tumors) Transferrin (decreased in ovarian tumors) Pre-albumin (decreased in ovarian ...
